Key terms
About GMED
Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GMED news
Yesterday
5:21am ET
Globus Medical price target raised to $85 from $83 at Barclays
Yesterday
3:29am ET
Barclays Reaffirms Their Buy Rating on Globus Medical (GMED)
Yesterday
12:46am ET
Globus Medical’s Strong Quarter Tempered by NuVasive Merger Complexities: A Hold Rating
May 08
10:05pm ET
Stifel Nicolaus Sticks to Its Buy Rating for Globus Medical (GMED)
May 08
12:00pm ET
Globus Medical rises 23.9%
May 08
10:00am ET
Globus Medical rises 23.8%
May 08
9:47am ET
Globus Medical rises 15.8%
May 08
7:06am ET
Globus Medical price target raised to $63 from $60 at BTIG
May 07
4:36pm ET
Globus Medical updates FY24 adjusted EPS view to $2.75-$2.85, consensus $2.69
May 07
4:35pm ET
Globus Medical reports Q1 adjusted EPS 72c, consensus 57c
Apr 26
6:30am ET
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Globus Medical (GMED) and Merck & Company (MRK)
Apr 17
4:00am ET
RBC Capital Sticks to Its Buy Rating for Globus Medical (GMED)
Mar 18
5:59am ET
Globus Medical upgraded to Buy from Neutral at BTIG
Mar 18
3:10am ET
Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Eli Lilly & Co (LLY) and Globus Medical (GMED)
Feb 22
8:50pm ET
Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED), Cochlear Limited (OtherCHEOF) and Nurix Therapeutics (NRIX)
Feb 22
5:06am ET
Barclays Remains a Buy on Globus Medical (GMED)
Feb 21
10:30am ET
Analysts Conflicted on These Healthcare Names: Globus Medical (GMED) and Crispr Therapeutics AG (CRSP)
Feb 21
9:26am ET
Globus Medical price target raised to $64 from $61 at Stifel
Feb 21
8:07am ET
Globus Medical: Strong Financials and Strategic Growth Post-NuVasive Merger Merit a Buy Rating
Feb 21
8:03am ET
Globus Medical (GMED) Gets a Buy from Stifel Nicolaus
Feb 21
8:00am ET
Analysts Conflicted on These Healthcare Names: Cooper Co (COO), Medtronic (MDT) and Globus Medical (GMED)
Feb 21
7:04am ET
Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED), Universal Health (UHS) and RAPT Therapeutics (RAPT)
Feb 21
6:44am ET
Globus Medical: Hold Rating Affirmed Amidst Modest Growth Projections and Integration Risks
Feb 21
6:10am ET
Analysts Offer Insights on Healthcare Companies: Illumina (ILMN) and Globus Medical (GMED)
Feb 21
5:31am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Medtronic (MDT), Globus Medical (GMED) and Zai Lab (ZLAB)
Feb 20
4:34pm ET
Globus Medical backs FY24 EPS view $2.68 to $2.70, consensus $2.69
Feb 20
4:32pm ET
Globus Medical reports Q4 EPS 60c, consensus 61c
Feb 16
8:07am ET
Stifel Nicolaus Sticks to Their Buy Rating for Globus Medical (GMED)
No recent press releases are available for GMED
GMED Financials
Key terms
Ad Feedback
GMED Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GMED Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
